Back to Browse Journals » Clinical Ophthalmology » Volume 5

Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial

Authors Patane MA, Cohen A, From S, Torkildsen G, Welch D, Ousler GW 3rd

Published Date May 2011 Volume 2011:5 Pages 633—643


Published 15 May 2011

Michael A Patane¹, Amy Cohen¹, Stephen From¹, Gail Torkildsen², Donna Welch³, George W Ousler III³
¹Eyegate Pharmaceuticals, Inc, Waltham, MA, USA; ²Andover Eye Associates, Andover, MA, USA; ³Ora, Inc, Andover, MA, USA

Purpose: To assess safety and efficacy of EGP-437 (dexamethasone phosphate 40 mg/mL [DP]) in dry eye patients.
Methods: The study employed a prospective, single-center, double-masked design utilizing a Controlled Adverse Environment (CAE). Patients (n = 103) with confirmed signs and symptoms of dry eye syndrome were randomized into 1 of 3 iontophoresis treatment groups: 7.5 mA-min at 2.5 mA (DP 7.5, n = 41); 10.5 mA-min at 3.5 mA (DP 10.5, n = 37); or 10.5 mA-min at 3.5 mA (placebo, n = 25). Three CAE visits and 4 follow-up visits occurred over 3 weeks. Patients meeting enrollment criteria received iontophoresis in both eyes after the second CAE exposure (visit 3) and before the third CAE exposure (visit 5). Primary efficacy endpoints were corneal staining and ocular discomfort. Secondary endpoints included tear film break-up time, ocular protection index (OPI), and symptomatology.
Results: The DP 7.5 and DP 10.5 treatment groups showed statistically significant improvements in signs and symptoms of dry eye at various time points; however, the primary endpoints were not achieved. The DP 7.5 treatment group exhibited statistically significant improvements in corneal staining (when comparing the differences between study entry and exit, 3 weeks, P = 0.039), OPI (immediately following the second treatment, P = 0.048) and ocular discomfort at follow-up visits (a week after the first treatment, P = 0.032; 24 hours after the second treatment, P = 0.0032). Treatment-emergent adverse events (AEs) were experienced by 87% of patients and were consistent across all treatment groups. Most AEs were mild and no severe AEs were observed.
Conclusion: Ocular iontophoresis of EGP-437 demonstrated statistically and clinically significant improvements in signs and symptoms of dry eye syndrome within a CAE model.

Keywords: iontophoresis, dry eye, Controlled Adverse Environment (CAE), ocular protection index (OPI)

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other articles by this author:

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%

Bergmann MT, Williams JI, Gomes PJ

Clinical Ophthalmology 2014, 8:1495-1505

Published Date: 13 August 2014

Measurement of ocular surface protection under natural blink conditions

Abelson R, Lane KJ, Angjeli E, Johnston P, Ousler G, Montgomery D

Clinical Ophthalmology 2011, 5:1349-1357

Published Date: 22 September 2011

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%

Jack V Greiner, Kimberly Edwards-Swanson, Avner Ingerman

Clinical Ophthalmology 2011, 5:87-93

Published Date: 13 January 2011

Readers of this article also read:

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt

Guan P, Lu Y, Qi J, Niu M, Lian R, Hu F, Wu W

International Journal of Nanomedicine 2011, 6:965-974

Published Date: 4 May 2011

Liraglutide in the management of type 2 diabetes

Estela Wajcberg, Amatur Amarah

Drug Design, Development and Therapy 2010, 4:279-290

Published Date: 22 October 2010

Comparison of preference and safety of powder and liquid lactulose in adult patients with chronic constipation

Charles F Barish, Bryan Voss, Byron Kaelin

Clinical and Experimental Gastroenterology 2010, 3:153-158

Published Date: 19 October 2010

Oxybutynin extended release for the management of overactive bladder: a clinical review

AM Arisco, EK Brantly, SR Kraus

Drug Design, Development and Therapy 2009, 3:151-161

Published Date: 26 May 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Effect of losartan on Doppler sonography indices in kidney transplant patients: A randomized clinical trial

Nader Nouri-Majalan, Reza Nafisi, Sarasadat Moghadasi-Mousavi

Vascular Health and Risk Management 2009, 5:97-100

Published Date: 10 December 2008